Xenon Continues R&D Spend, No Revenue in Q2

TL;DR

**XENE is a pure-play R&D bet; no revenue means it's all about pipeline execution.**

AI Summary

Xenon Pharmaceuticals Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for the three months ended June 30, 2025, was not explicitly stated in the provided data, but research and development expenses for Azetukalner were incurred. Key business changes include ongoing development of Azetukalner and other pre-clinical programs, with expenses noted for both Burnaby, British Columbia, and Needham, Massachusetts operations. Financial risks include reliance on external funding given the lack of revenue and significant R&D expenditures. The strategic outlook focuses on advancing its pipeline, particularly Azetukalner, which is a primary driver of current operational costs. The company's financial position includes various investments such as guaranteed investment certificates and corporate debt securities, with fair value measurements indicating a focus on managing its cash runway.

Why It Matters

For investors, Xenon's continued lack of revenue underscores its high-risk, high-reward profile, typical of a clinical-stage biotech. The focus on advancing Azetukalner and other pre-clinical programs is critical, as any clinical setbacks could significantly impact valuation. Employees' job security is tied to successful pipeline progression and continued funding. Customers, primarily future patients, depend on the successful development and approval of these drug candidates. In the broader market, Xenon's progress contributes to the competitive landscape of neurological disorder treatments, potentially shifting market dynamics if Azetukalner proves effective.

Risk Assessment

Risk Level: high — The risk level is high due to Xenon Pharmaceuticals Inc.'s pre-revenue stage, as indicated by 'no revenue' for the three and six months ended June 30, 2025. The company's financial health is entirely dependent on its ability to raise capital and successfully develop its drug candidates, particularly Azetukalner, which incurs significant R&D expenses.

Analyst Insight

Investors should monitor clinical trial progress for Azetukalner closely and assess the company's cash burn rate. Consider this a speculative investment, suitable only for those with a high-risk tolerance and a long-term horizon, as profitability is years away.

Financial Highlights

revenue

$0

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three and six months ended June 30, 2025, indicating pre-commercial stage)
• 2025-06-30 — Conformed Period of Report (end date of the reporting period for the 10-Q)
• 2025-08-11 — Filed As Of Date (date the 10-Q was filed with the SEC)

Key Players & Entities

• Xenon Pharmaceuticals Inc. (company) — filer of the 10-Q
• Azetukalner (drug) — key drug candidate in development
• Burnaby, British Columbia (location) — location of operations for Xenon Pharmaceuticals Inc.
• Needham, Massachusetts (location) — location of operations for Xenon Pharmaceuticals Inc.
• 0001582313 (company) — Central Index Key (CIK) for Xenon Pharmaceuticals Inc.
• 03 Life Sciences (company) — organization name associated with Xenon Pharmaceuticals Inc.

FAQ

Risk Factors

• Reliance on External Funding [high — financial]: Xenon Pharmaceuticals Inc. has no revenue and significant research and development expenditures, making it heavily reliant on external funding to sustain its operations and advance its pipeline. This dependence creates a risk if funding sources become unavailable or insufficient.
• Research and Development Expenses [high — operational]: The company incurs substantial costs for the development of Azetukalner and other pre-clinical programs. These expenses, particularly for operations in Burnaby, British Columbia, and Needham, Massachusetts, represent a significant drain on resources and are subject to the inherent risks of drug development, including clinical trial failures.
• Pre-Commercial Stage [high — market]: As a pre-commercial stage company, Xenon Pharmaceuticals Inc. has no current revenue streams. Its success is entirely dependent on the future commercialization of its drug candidates, which is subject to market acceptance, regulatory approvals, and competitive pressures.

Industry Context

Xenon Pharmaceuticals Inc. operates in the highly competitive pharmaceutical industry, characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. The industry is driven by innovation in discovering and developing novel therapies for unmet medical needs. Companies in this sector face challenges related to clinical trial success rates, patent expirations, and market access.

Regulatory Implications

As a pharmaceutical company, Xenon is subject to extensive regulation by health authorities like the FDA and Health Canada. The development and approval process for drugs like Azetukalner are lengthy and costly, with a high risk of failure. Compliance with Good Manufacturing Practices (GMP) and other regulatory standards is critical throughout the drug lifecycle.

What Investors Should Do

1. Monitor R&D progress and clinical trial results for Azetukalner.
2. Assess the company's ability to secure future funding.
3. Evaluate the company's cash burn rate and runway.

Key Dates

• 2025-06-30: End of Reporting Period — This date marks the conclusion of the period covered by the 10-Q filing, providing a snapshot of the company's financial position and performance.
• 2025-08-11: 10-Q Filing Date — This is the date Xenon Pharmaceuticals Inc. officially submitted its quarterly report to the SEC, making the information publicly available.

Glossary

Azetukalner

A drug candidate being developed by Xenon Pharmaceuticals Inc. (It is a primary driver of current operational costs and a key focus of the company's research and development efforts.)

Pre-clinical programs

Research and development activities conducted before human clinical trials, aimed at assessing the safety and efficacy of potential drug candidates. (These programs represent a significant portion of Xenon's R&D expenses and future potential.)

Guaranteed Investment Certificates (GICs)

A type of investment offered by financial institutions that guarantees the principal amount and a fixed rate of interest over a specified term. (Xenon holds GICs as part of its investment portfolio, indicating a strategy to manage its cash reserves with a focus on capital preservation.)

Corporate Debt Securities

Debt instruments issued by corporations, representing a loan made by an investor to the corporation. (These are held by Xenon as investments, suggesting a diversified approach to managing its liquid assets.)

Fair Value Measurements

The price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. (Xenon uses fair value measurements for its investments, indicating a focus on accurately valuing its assets and managing its financial position.)

Year-Over-Year Comparison

Information to compare key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text. The company is in a pre-commercial stage with no revenue reported for the current period, consistent with its prior financial reporting.

Filing Documents

• xene-20250630.htm (10-Q) — 2547KB
• xene-ex10_1.htm (EX-10.1) — 89KB
• xene-ex10_2.htm (EX-10.2) — 184KB
• xene-ex31_1.htm (EX-31.1) — 16KB
• xene-ex31_2.htm (EX-31.2) — 16KB
• xene-ex32_1.htm (EX-32.1) — 12KB
• xene-ex32_2.htm (EX-32.2) — 11KB
• img3581121_0.jpg (GRAPHIC) — 235KB
• img3581121_1.jpg (GRAPHIC) — 235KB
• 0000950170-25-106599.txt ( ) — 9673KB
• xene-20250630.xsd (EX-101.SCH) — 878KB
• xene-20250630_htm.xml (XML) — 1754KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Shareholders' Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 15

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 23

Controls and Procedures

Item 4. Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION 24

Legal Proceedings

Item 1. Legal Proceedings 24

Risk Factors

Item 1A. Risk Factors 24

Other Information

Item 5. Other Information 64

Exhibits

Item 6. Exhibits 65

SIGNATURES

SIGNATURES 66 In this Quarterly Report on Form 10-Q, "we," "our," "us," "Xenon," and "the Company" refer to Xenon Pharmaceuticals Inc. and its subsidiary. "Xenon" and the Xenon logo are the property of Xenon Pharmaceuticals Inc. and are registered in the United States and used or registered in various other jurisdictions. This report contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report may appear without the or symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. - 1 - Risk Factors Summary Our business is subject to numerous risks and uncertainties, including those highlighted in the section of this report captioned "Risk Factors." The following is a summary of the principal risks we face: We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We will need to raise additional funding, which may not be available on acceptable terms, if at all. Failure to obtain capital when needed may force us to delay, limit or terminate our product discovery and development programs or commercialization efforts or other operations. Our business substantially depends upon the successful development of azetukalner. If we are unable to obtain regulatory approval for, and successfully commercialize, azetukalner, our business may be materially harmed. Clinical trials may fail to demonstrate adequately the safety and efficacy of our, or our collaborators', product candidates at any stage of clinical development. Terminating the development of any of our, or our collaborato

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

Fina ncial Statements

Item 1. Fina ncial Statements XENON PHARMACEUTICALS INC. Condensed Consolidated Ba lance Sheets (Unaudited) (Expressed in thousands of U.S. dollars except share amounts) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 135,381 $ 142,712 Marketable securities (note 5) 352,164 484,193 Other receivables 1,097 1,469 Prepaid expenses and other current assets 11,610 6,890 Total current assets 500,252 635,264 Marketable securities, long-term (note 5) 137,297 127,496 Operating lease right-of-use asset, net (note 6) 7,290 7,939 Property, plant and equipment, net 9,205 10,278 Deferred tax assets 11,049 9,666 Prepaid expenses, long-term 9,188 7,496 Total assets $ 674,281 $ 798,139 Liabilities and shareholders' equity Current liabilities: Accounts payable and accrued liabilities (note 7) $ 31,588 $ 34,221 Operating lease liability (note 6) 1,459 1,369 Total current liabilities 33,047 35,590 Operating lease liability, long-term (note 6) 7,256 7,646 Total liabilities 40,303 43,236 Shareholders' equity: Common shares, without par value; unlimited shares authorized; issued and outstanding: 76,939,811 (December 31, 2024 - 76,416,086 ) (note 8) 1,469,196 1,456,836 Additional paid-in capital 213,892 199,149 Accumulated deficit ( 1,049,223 ) ( 899,470 ) Accumulated other comprehensive income (loss) 113 ( 1,612 ) Total shareholders' equity 633,978 754,903 Total liabilities and shareholders' equity $ 674,281 $ 798,139 Commitments and contingencies (note 11) See accompanying notes to the condensed consolidated financial statements. - 3 - XENON PHARMACEUTICALS INC. Condensed Consolidated St atements of Operations and Comprehensive Loss (Unaudited) (Expressed in thousands of U.S. dollars except share and per share amounts) Three Months Ended June 30, Six Months E

View Full Filing

View this 10-Q filing on SEC EDGAR